Prednisone in treatment of allergen-associated angio-immunoblastic lymphadenopathy.
Angio-immunoblastic lymphadenopathy with dysproteinaemia (A.I.L.D.) is a lymphoproliferative disorder associated in one third of the patients with exposure to an allergen. In four patients with allergen-associated A.I.L.D. single cytotoxic drugs were ineffective but maintenance low-dose prednisone for 6--12 months induced complete remission for up to 13 years. In contrast, three patients with non-allergen-associated A.I.L.D. did not respond to prednisone but achieved remission with combination chemotherapy.
D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects; D005052:Eucalyptus; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy* / Q000209:etiology; D007252:Influenza Vaccines / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects; D010939:Plant Poisoning / Q000150:complications; D010946:Plants, Medicinal; D011241:Prednisone / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013552:Swine; D013997:Time Factors
D000970:Antineoplastic Agents; D002511:Cephalosporins; D007252:Influenza Vaccines; D010406:Penicillins; D011241:Prednisone